X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7668) 7668
Publication (745) 745
Book Review (688) 688
Conference Proceeding (15) 15
Book Chapter (8) 8
Dissertation (5) 5
Magazine Article (5) 5
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7241) 7241
humans (6475) 6475
deoxycytidine - analogs & derivatives (5608) 5608
oncology (3538) 3538
female (2970) 2970
deoxycytidine - pharmacology (2803) 2803
gemcitabine (2390) 2390
deoxycytidine - administration & dosage (2366) 2366
male (2342) 2342
animals (2214) 2214
pharmacology & pharmacy (2081) 2081
middle aged (1962) 1962
cell line, tumor (1908) 1908
chemotherapy (1865) 1865
cancer (1802) 1802
aged (1788) 1788
adult (1549) 1549
antineoplastic combined chemotherapy protocols - therapeutic use (1472) 1472
mice (1412) 1412
deoxycytidine - therapeutic use (1405) 1405
antimetabolites, antineoplastic - pharmacology (1221) 1221
pancreatic neoplasms - drug therapy (1165) 1165
pancreatic cancer (1047) 1047
treatment outcome (997) 997
deoxycytidine - adverse effects (994) 994
capecitabine (963) 963
pancreatic neoplasms - pathology (896) 896
apoptosis (864) 864
antineoplastic agents - pharmacology (859) 859
fluorouracil - analogs & derivatives (849) 849
dose-response relationship, drug (842) 842
antineoplastic combined chemotherapy protocols - adverse effects (808) 808
expression (804) 804
therapy (773) 773
apoptosis - drug effects (766) 766
antimetabolites, antineoplastic - therapeutic use (727) 727
research (714) 714
cisplatin (649) 649
medicine & public health (647) 647
antimetabolites, antineoplastic - administration & dosage (640) 640
cell proliferation - drug effects (639) 639
dna methylation (633) 633
drug synergism (617) 617
pharmacology/toxicology (612) 612
fluorouracil - administration & dosage (609) 609
carcinoma (607) 607
care and treatment (604) 604
biochemistry & molecular biology (595) 595
azacitidine - pharmacology (588) 588
azacitidine - analogs & derivatives (581) 581
drug resistance, neoplasm (574) 574
lung neoplasms - drug therapy (563) 563
5-aza-2'-deoxycytidine (560) 560
aged, 80 and over (557) 557
survival (552) 552
drug administration schedule (551) 551
tumors (551) 551
cell survival - drug effects (544) 544
tumor cells, cultured (540) 540
analysis (531) 531
pancreatic neoplasms - metabolism (527) 527
mice, nude (525) 525
deoxycytidine - pharmacokinetics (509) 509
antineoplastic agents (502) 502
trial (501) 501
xenograft model antitumor assays (497) 497
cancer research (494) 494
pharmacology (487) 487
drug therapy (480) 480
cells (474) 474
antimitotic agents (473) 473
deoxycytidine kinase (471) 471
combination (467) 467
antineoplastic combined chemotherapy protocols - pharmacology (457) 457
antineoplastic combined chemotherapy protocols - administration & dosage (451) 451
in-vitro (449) 449
5-fluorouracil (448) 448
article (443) 443
deoxycytidine - metabolism (436) 436
methylation (435) 435
breast neoplasms - drug therapy (434) 434
time factors (433) 433
carcinoma, non-small-cell lung - drug therapy (432) 432
neoplasms - drug therapy (429) 429
metastasis (425) 425
cisplatin - administration & dosage (423) 423
adenocarcinoma - drug therapy (418) 418
dna (416) 416
adenocarcinoma (413) 413
antineoplastic agents - therapeutic use (413) 413
antimetabolites, antineoplastic - adverse effects (408) 408
disease-free survival (408) 408
gene expression (401) 401
phosphorylation (401) 401
survival analysis (392) 392
resistance (384) 384
health aspects (379) 379
pharmacokinetics (378) 378
cell line (376) 376
inhibition (371) 371
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7527) 7527
Chinese (51) 51
Japanese (37) 37
French (18) 18
Russian (18) 18
Spanish (9) 9
German (8) 8
Italian (3) 3
Hungarian (2) 2
Danish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2003, Volume 2, Issue 10, pp. 971 - 984
Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin... 
SIGNAL-TRANSDUCTION | ACUTE-LEUKEMIA CELLS | ONCOLOGY | ACETYLATION | RESISTANCE | RECEPTOR | RAF-1 | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | TAXOL-INDUCED APOPTOSIS | HSP90 FUNCTION | Chromatin - metabolism | Phosphorylation | Taxoids - pharmacology | Coloring Agents - pharmacology | Annexin A5 - pharmacology | Humans | Epothilones - pharmacology | Multienzyme Complexes - metabolism | Deoxycytidine - pharmacology | Proteasome Endopeptidase Complex | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Sepharose - pharmacology | Cysteine Endopeptidases - metabolism | Flow Cytometry | Cyclins - metabolism | Time Factors | Antimetabolites, Antineoplastic - pharmacology | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Detergents - pharmacology | Receptor, ErbB-2 - biosynthesis | Cyclin-Dependent Kinase Inhibitor p21 | Antibodies, Monoclonal - pharmacology | Down-Regulation | Enzyme Inhibitors - pharmacology | Tetrazolium Salts - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Blotting, Western | Precipitin Tests | Blotting, Northern | Cell Line, Tumor | Histone Deacetylase Inhibitors | Thiazoles - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Deoxycytidine - analogs & derivatives | Microscopy, Fluorescence | Trastuzumab | Apoptosis | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 825 - 837
The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is... 
Medicine & Public Health | Cell cycle | Oncology | In vivo antitumor activity | Pharmacology/Toxicology | Combination therapy | LY2835219 | Kinase inhibitor | CDK4/6 inhibitor | Cdk4/6 inhibitor | LUNG | HUMAN BREAST | PHOSPHORYLATION | CANCER | DEPENDENT KINASE 4/6 | CONSTITUTIVELY ACTIVATED FLT3 | ONCOLOGY | BRAIN METASTASES | RESTRICTION POINT | TUMOR-SUPPRESSOR | PHARMACOLOGY & PHARMACY | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Neoplasms - metabolism | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Deoxycytidine - therapeutic use | Aminopyridines - therapeutic use | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Retinoblastoma Protein - metabolism | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Retinoblastoma Protein - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Dosage and administration | Research | Gemcitabine | Studies | Protein expression | Inhibitor drugs | Kinases | Cancer therapies | Analysis | Index Medicus | CDK4 | Preclinical Studies | 6 inhibitor
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2012, Volume 11, Issue 2, pp. 427 - 438
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2006, Volume 12, Issue 8, pp. 2640 - 2646
Purpose: Tumor necrosis factor-related apoptosis–inducing ligand (TRAIL/Apo2L) exhibits potent antitumor activity on systemic administration in nonhuman... 
apoptosis | TRAIL | primary human hepatocytes | chemotherapy | HEPATOCELLULAR-CARCINOMA CELLS | APOPTOSIS-INDUCING LIGAND | ONCOLOGY | HUMAN HEPATOCYTES | IN-VIVO | RECEPTOR | TUMORICIDAL ACTIVITY | MONOCLONAL-ANTIBODY | DEATH | NF-KAPPA-B | FAMILY | Immunohistochemistry | Apoptosis Regulatory Proteins - pharmacology | Apoptosis - drug effects | Gene Expression - genetics | Humans | Tumor Necrosis Factor-alpha - genetics | GPI-Linked Proteins | Apoptosis - genetics | Deoxycytidine - pharmacology | Hepatocytes - metabolism | Receptors, TNF-Related Apoptosis-Inducing Ligand | Organoplatinum Compounds - pharmacology | Receptors, Tumor Necrosis Factor, Member 10c | Dose-Response Relationship, Drug | Tumor Necrosis Factor Decoy Receptors | Hepatocytes - cytology | TNF-Related Apoptosis-Inducing Ligand | Time Factors | Apoptosis Regulatory Proteins - genetics | Antineoplastic Agents - pharmacology | Hepatocytes - drug effects | Camptothecin - analogs & derivatives | Receptors, Tumor Necrosis Factor - genetics | Receptors, Tumor Necrosis Factor - metabolism | Cell Survival - drug effects | Membrane Glycoproteins - pharmacology | Cells, Cultured | Etoposide - pharmacology | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Membrane Glycoproteins - genetics | Tumor Necrosis Factor-alpha - pharmacology | Cell Line, Tumor | Fluorouracil - pharmacology | Camptothecin - pharmacology | Deoxycytidine - analogs & derivatives | Index Medicus | in-vivo | tumoricidal activity | monoclonal-antibody | hepatocellular-carcinoma cells | human hepatocytes | receptor | death | nf-kappa-b | family | apoptosis-inducing ligand
Journal Article
Antiviral Research, ISSN 0166-3542, 02/2016, Volume 126, pp. 69 - 80
Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are... 
Antiviral agents | Innate immunity | Virus-host interaction | Immune responses | Influenza A virus | HUMAN MACROPHAGES | INFLUENZA-A-VIRUS | VIRAL-INFECTIONS | NS1 PROTEIN | RNA-BINDING | ANTIVIRAL RESPONSES | NEURAMINIDASE INHIBITORS | VIROLOGY | EPITHELIAL-CELLS | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | PYRIMIDINE BIOSYNTHESIS | Interferon-alpha - drug effects | Coinfection - drug therapy | Humans | Deoxycytidine - pharmacology | Phosphoproteins - metabolism | Salicylates - pharmacology | Macrophages - virology | Influenza, Human - virology | Antineoplastic Agents - pharmacology | Influenza, Human - drug therapy | Macrophages - immunology | Amides - pharmacology | Influenza A virus - physiology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Cytokines - metabolism | Immunity, Innate - drug effects | RNA, Viral - biosynthesis | Cells, Cultured | Coinfection - virology | Interferon-alpha - immunology | Pyrroles - pharmacology | Lipopolysaccharides - pharmacology | Macrophages - drug effects | Oxazoles - pharmacology | Thiazoles - pharmacology | Influenza A virus - drug effects | Virus Replication - physiology | Deoxycytidine - analogs & derivatives | Immunologic Factors - pharmacology | Influenza, Human - immunology | Epidemics | Analysis | Influenza | Interferon alpha | Global economy | Biological response modifiers | Health aspects | Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 07/2012, Volume 26, Issue 11, pp. 1371 - 1385
Background: The effect of specific antiretrovirals on inflammation is unclear. Methods: A5224s was a substudy of A5202, which randomized HIV-infected... 
endothelial activation markers | abacavir | C-reactive protein | TNF alpha | inflammation markers | interleukin-6 | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | IMMUNOLOGY | HIV-INFECTED PATIENTS | TENOFOVIR-EMTRICITABINE | INDIVIDUAL ANTIRETROVIRAL DRUGS | VIROLOGY | CLINICAL-TRIALS | ACUTE MYOCARDIAL-INFARCTION | Anti-HIV Agents - pharmacology | Humans | Tumor Necrosis Factor-alpha - blood | Deoxycytidine - pharmacology | Male | Inflammation - blood | Tenofovir | Acquired Immunodeficiency Syndrome - immunology | C-Reactive Protein - metabolism | Interleukin-6 - blood | Atazanavir Sulfate | Adult | Female | Ritonavir - pharmacology | C-Reactive Protein - drug effects | Acquired Immunodeficiency Syndrome - blood | Emtricitabine | Dideoxynucleosides - pharmacology | HIV-1 - metabolism | Adenine - analogs & derivatives | Adenine - pharmacology | Inflammation - immunology | Biomarkers - blood | Acquired Immunodeficiency Syndrome - drug therapy | Organophosphonates - pharmacology | Tumor Necrosis Factor-alpha - drug effects | Benzoxazines - pharmacology | Lamivudine - pharmacology | Pyridines - pharmacology | Oligopeptides - pharmacology | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | nucleoside reverse transcriptase inhibitors | RNA | Ritonavir | tenofovir | Lamivudine | Inflammation | Efavirenz | CD4 antigen | Cell adhesion molecules | Interleukin 6 | Abacavir | Age | Tumor necrosis factor- alpha | Index Medicus | AIDS/HIV
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | GENE-MUTATIONS | LUNG-CANCER | FUNCTIONAL-ACTIVITY | ONCOLOGY | ABL TYROSINE KINASE | MITOMYCIN-C | PANCREATIC-CANCER | RANDOMIZED-TRIAL | PHASE-II | COMPLEMENTATION GROUP | CARCINOMA | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Index Medicus
Journal Article
Cancer Discovery, ISSN 2159-8274, 06/2012, Volume 2, Issue 6, pp. 524 - 539
Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies.... 
DNA-DAMAGING AGENTS | MUTATION STATUS | ONCOLOGY | AGGRESSIVE BREAST-CANCER | GENOME INTEGRITY | CYCLIN B1 | CHROMOSOME CONDENSATION | INDUCED G CHECKPOINT | P53 MUTANT-CELLS | TUMOR-CELLS | KINASE INHIBITOR | Protein Kinases - metabolism | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Apoptosis - drug effects | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Quinolines - pharmacology | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | DNA-Binding Proteins - metabolism | Deoxycytidine - therapeutic use | Cyclins - metabolism | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pyrazoles - pharmacology | Cell Line | Thiophenes - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Breast Neoplasms - drug therapy | Enhancer of Zeste Homolog 2 Protein | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Polycomb Repressive Complex 2 | Urea - therapeutic use | Animals | Mitosis - drug effects | Tumor Burden - drug effects | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | S Phase - drug effects | Thiazoles - pharmacology | Deoxycytidine - analogs & derivatives | Urea - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 06/2013, Volume 73, Issue 12, pp. 3683 - 3691
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we... 
CHECKPOINT KINASE 1 | IN-VITRO | ONCOLOGY | XANTHINE DERIVATIVES | DNA-DAMAGE RESPONSE | PROTEIN-KINASE | TUMOR-CELLS | MYELOGENOUS LEUKEMIA-CELLS | RADIOSENSITIZING AGENT | MAMMALIAN-CELLS | CHK1 INHIBITOR | Protein Kinases - metabolism | Protein Kinases - genetics | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Deoxycytidine - pharmacology | Immunoblotting | Sulfones - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | RNA Interference | BRCA1 Protein - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Topotecan - pharmacology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Signal Transduction - genetics | cdc25 Phosphatases - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | Pyrimidines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Signal Transduction - drug effects | Cell Line, Tumor | Benzimidazoles - pharmacology | Checkpoint Kinase 1 | Pyrazines - pharmacology | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Index Medicus | homologous recombination | ovarian cancer | Poly(ADP-ribose) polymerase | veliparib | gemcitabine | BRCA1 | cisplatin | BRCA2 | topotecan
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 783 - 794
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 05/2012, Volume 134, Issue 18, pp. 7978 - 7982
Journal Article
BMC Cancer, ISSN 1471-2407, 08/2014, Volume 14, Issue 1, pp. 570 - 570
Background: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent... 
Triple-negative | Breast cancer | Chk1 | V158411 | DNA repair | Ovarian cancer | POLY(ADP-RIBOSE) POLYMERASE